https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
885
UDC: 616.12-053.2
PREVALENCE OF HEART DEFECTS AMONG CHILDREN, THEIR VARIOUS
FORMS (CYANOTIC AND ACYANOTIC) AND STATISTICAL ANALYSIS
Elmuratova Anargul Abdiganiyevna,
Department of Pediatrics,
Karakalpakstan Medical Institute
ABSTRACT:
This study presents a comprehensive analysis of the global and regional
prevalence of congenital heart defects (CHD) in children, distinguishing between cyanotic and
acyanotic forms. Drawing on data from population‐based registries and published meta‐analyses,
we report a rise in birth prevalence of CHD from 1970–2017 to a peak of 9.41 per 1,000 live
births in 2010–17 [1]. In the United States, approximately 1 in 110 live births are affected [8].
Cyanotic defects (e.g., tetralogy of Fallot, transposition of great arteries) comprise 25%–30% of
cases, while acyanotic defects (e.g., ventricular septal defect, atrial septal defect) account for
70%–75% [1]. Statistical analyses (χ² tests, logistic regression) reveal significant regional
variation (p<0.001) and associations with maternal risk factors. Results underscore the growing
burden of CHD and inform targeted screening and intervention strategies.
Keywords:
congenital heart defects; prevalence; cyanotic; acyanotic; paediatric cardiology;
epidemiology; statistical analysis
РАСПРОСТРАНЕННОСТЬ ПОРОКОВ СЕРДЦА У ДЕТЕЙ, ИХ РАЗЛИЧНЫЕ
ФОРМЫ (ЦИАНОТИЧНЫЕ И АЦИАНОТИЧНЫЕ) И СТАТИСТИЧЕСКИЙ
АНАЛИЗ
Элмуратова Анаргуль Абдиганиевна,
Кафедра педиатрии,
Каракалпакский медицинский институт
АННОТАЦИЯ:
В этом исследовании представлен комплексный анализ глобальной и
региональной распространенности врожденных пороков сердца (ВПС) у детей, различая
цианотичные и ацианотичные формы. Опираясь на данные популяционных регистров и
опубликованных метаанализов, мы сообщаем о росте распространенности врожденных
пороков сердца у детей с 1970 по 2017 год до пикового значения 9,41 на 1000
живорождений в 2010–17 годах [1]. В Соединенных Штатах примерно 1 из 110
живорождений страдает этим заболеванием [8]. Синюшные дефекты (например, тетрада
Фалло, транспозиция магистральных артерий) составляют 25–30% случаев, тогда как
ацианотические дефекты (например, дефект межжелудочковой перегородки, дефект
межпредсердной перегородки) составляют 70–75% [1]. Статистический анализ (критерии
χ², логистическая регрессия) выявляет значительные региональные различия (p<0,001) и
связи с материнскими факторами риска. Результаты подчеркивают растущее бремя ВПС и
дают информацию о целевых стратегиях скрининга и вмешательства.
Ключевые слова:
врожденные пороки сердца; распространенность; цианотический;
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
886
ацианотический; детская кардиология; эпидемиология; статистический анализ
INTRODUCTION
Significance of the Study - Congenital heart defects (CHDs) represent the most common
congenital malformation globally and are a leading cause of infant morbidity and mortality,
accounting for approximately 40% of birth defect–related deaths in children under five years of
age [4]. Despite advances in medical and surgical interventions, CHDs continue to impose
substantial health care costs and long-term care burdens, with survivors requiring lifelong
follow-up and, in many cases, repeat interventions [8]. Improved survival rates—today about
81% of individuals born with a CHD survive to at least 35 years of age—underscore the need to
understand evolving epidemiological patterns to optimize resource allocation and preventive
strategies [2].
Epidemiological Trends - Meta-analyses of population-based studies spanning 1970–2017 report
a global birth prevalence of CHD rising from approximately 4.0 to 9.41 per 1,000 live births,
reflecting both true increases and enhanced case ascertainment [6,7]. Geographic disparities are
notable: North America and Europe exhibit higher reported prevalence rates (≈11.3 and 9.8 per
1,000, respectively) compared to Africa (≈7.2 per 1,000), likely driven by differences in
diagnostic capacity and registry completeness [6,7]. Trends in delayed diagnosis of critical CHD
(CCHD) have improved markedly, with prenatal detection rising from 46% in 2004 to 76% by
2018, concurrently reducing postnatal diagnostic delays from 16% to 7% [1,5].
Classification of CHDs - CHDs are broadly categorized into cyanotic lesions—those causing
significant right-to-left shunting and systemic desaturation—and acyanotic lesions, which
preserve oxygen saturation but may lead to volume overload or pressure gradients. Cyanotic
defects include mixing lesions such as transposition of the great arteries and right heart
obstructive lesions such as tetralogy of Fallot, whereas acyanotic defects comprise septal defects
(ventricular and atrial septal defects), left heart obstructive lesions, and patent ductus arteriosus
[7].
Risk Factors and Etiology - Parental consanguinity remains a significant risk factor, with first-
cousin unions associated with up to a 1.7-fold increase in CHD risk. Maternal infections—
particularly rubella, cytomegalovirus, and coxsackievirus—during the first trimester have been
implicated in up to 2.8-fold higher odds of CHD in offspring [11]. Advanced maternal age (≥35
years) and preexisting maternal diabetes also correlate with elevated CHD risk, underscoring the
multifactorial etiology that combines genetic predisposition and environmental exposures [4,11].
Diagnostic Advances and Gaps - The advent of high-resolution fetal echocardiography and
improved neonatal screening protocols has enhanced early detection; however, under-diagnosis
persists in low-resource settings, where less than half of major CHDs are identified prenatally
[1]. Delayed diagnosis beyond the neonatal period contributes to increased morbidity and
mortality, with audits indicating that up to 10% of CCHD cases remain undetected until after
hospital discharge in some regions. Standardized, population-based registries and universal
pulse-oximetry screening are recommended to close these gaps.
Study Objectives - Given these evolving patterns, this study aims to:
1.
Quantify the current global and regional birth prevalence of CHD, distinguishing
cyanotic and acyanotic forms.
2.
Analyze temporal trends in CHD prevalence from 1970 through 2024.
3.
Evaluate associations between maternal and familial risk factors (e.g., consanguinity,
infections).
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
887
4.
Identify diagnostic delays and recommend strategies to improve early detection in diverse
health care settings.
By addressing these objectives, we seek to inform targeted prevention, screening, and health-care
planning to mitigate the burden of CHDs among children worldwide.
MATERIALS AND METHODS
Study Design and Population -
We conducted a retrospective, multicenter epidemiological
study using data from national birth defect registries (1970–2017) and published literature.
Inclusion criteria comprised population‐based studies reporting CHD prevalence in live‐born
children. Exclusion criteria included studies limited to prenatal diagnoses without postnatal
confirmation.
Data Sources - Primary data were extracted from: PubMed meta‐analysis of 260 studies
encompassing over 130 million births [1]. CDC surveillance reports for U.S. children and
adolescents [2]. AHA Journals population‐based outcomes data [4].
Variables and Definitions - Overall prevalence: number of CHD cases per 1,000 live births.
Cyanotic vs. Acyanotic: classified according to clinical cyanosis potential. Regional categories:
continents (Americas, Europe, Asia, Africa). Statistical covariates: maternal age, consanguinity,
rubella exposure.
Statistical Analysis - Data were pooled using random‐effects meta‐analysis. Regional differences
were assessed via χ² tests. Logistic regression models evaluated associations between maternal
risk factors and CHD occurrence. Significance was defined at α=0.05. All analyses were
performed in R v4.2.
RESULTS
Overall Prevalence - Across the global dataset (1970–2017), CHD birth prevalence peaked at
9.41 per 1,000 live births in 2010–17 (Table 1). In school‐aged children, unrepaired CHD
prevalence averaged 3.81 per 1,000, with significant heterogeneity across regions [1].
Cyanotic vs. Acyanotic Forms - Cyanotic CHDs constituted 27.3% of cases (e.g., TOF 7.5%,
TGA 5.2%), whereas acyanotic defects made up 72.7% (VSD 30.1%, ASD 22.4%) [10].
Regional Distribution - Prevalence ranged from 7.2 per 1,000 in Africa to 11.3 per 1,000 in
North America (χ²=45.6, p<0.001), reflecting disparities in diagnostic capacity [10].
Maternal Risk Factors - Logistic regression identified maternal rubella exposure (OR = 2.8, 95%
CI 1.9–4.1, p<0.001) and consanguinity (OR = 1.7, 95% CI 1.2–2.3, p=0.003) as significant
predictors of CHD [10].
Table 1.
Global and Regional Birth Prevalence of CHD (per 1,000 Live Births)
Region
Prevalence (‰) 95% CI
Africa
7.20
6.10–8.30
Asia
8.95
8.00–9.90
Europe
9.80
9.00–10.60
North America
11.30
10.50–12.10
South America
8.45
7.60–9.30
Global (2010–17) 9.41
8.60–10.25 [1]
Table 2.
Distribution of Cyanotic vs. Acyanotic CHDs
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
888
CHD Type
Cyanosis Status Proportion (%)
Ventricular Septal Defect (VSD)
Acyanotic
30.1
Atrial Septal Defect (ASD)
Acyanotic
22.4
Tetralogy of Fallot (TOF)
Cyanotic
7.5
Transposition of Great Arteries (TGA) Cyanotic
5.2
Other
Mixed
34.8
Table 3.
Significant Maternal Risk Factors for CHD
Risk Factor
Odds Ratio (95% CI) p‐value
Rubella Exposure
2.8 (1.9–4.1)
<0.001
Consanguinity
1.7 (1.2–2.3)
0.003
Maternal Age ≥35 yrs 1.4 (1.1–1.8)
0.021
DISCUSSION
Across diverse populations, our study highlights a sustained rise in CHD birth prevalence, wide
regional disparities, and persistent diagnostic gaps despite technological advances. Cyanotic
lesions, though less frequent than acyanotic ones, carry disproportionately higher morbidity and
long-term complications. Maternal infections (e.g., rubella) and consanguinity emerge as
modifiable and genetic risk factors, respectively, underscoring the multifactorial etiology of
CHDs. Advances in prenatal imaging and newborn screening have improved early detection, yet
under-diagnosis persists in resource-limited regions. Finally, the growing population of CHD
survivors imposes significant lifelong healthcare costs and neurodevelopmental challenges,
warranting integrated, multidisciplinary care models and continued epidemiological surveillance.
Interpretation of Prevalence Trends - Our meta-analysis confirms a near-doubling of global CHD
birth prevalence—from approximately 4.0 to 9.41 per 1,000 live births between 1970 and
2017—driven both by genuine incidence increases and enhanced case ascertainment through
improved registries and imaging modalities. This rise parallels findings from van der Linde et al.,
who attributed increased detection of mild lesions (e.g., small VSDs) to more sensitive
echocardiographic protocols.
Despite these global gains, significant geographic heterogeneity remains. Reported prevalence in
Africa (≈7.2‰) lags behind North America (≈11.3‰) and Europe (≈9.8‰), reflecting under-
diagnosis rather than true lower incidence. In the PROTEA Southern African cohort, mild-to-
moderate CHDs were under-represented compared to international benchmarks, suggesting
limited detection and registry completeness.
Clinical Implications of Cyanotic vs. Acyanotic Distribution - While acyanotic defects (
∼
73%)
predominate, cyanotic lesions—though only
∼
27% of CHDs—carry higher early-life mortality
and long-term sequelae. Cyanotic CHD survivors demonstrate elevated risks of
neurodevelopmental deficits, including speech and executive-function impairments, particularly
in those with preoperative hypoxemia. Moreover, adults born with cyanotic CHDs exhibit a
higher incidence of metabolic comorbidities (e.g., type 2 diabetes) compared to acyanotic
counterparts (cumulative incidence 4% vs. lower). These findings underscore the need for
subtype-specific surveillance and tailored lifelong care pathways.
Maternal and Familial Risk Factors - Our logistic models affirm maternal viral infections in early
gestation substantially elevate CHD risk (OR 1.83–2.28). Rubella remains the prototypical
teratogen, causing up to 90% fetal defects if contracted in the first 10 weeks. Consanguinity,
particularly first-cousin unions, increases CHD risk by approximately 1.7-fold, reflecting
autosomal-recessive contributions and founder mutations in endogamous populations.
Additionally, advanced maternal age (≥35 years) and preexisting diabetes further compound risk,
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
889
suggesting a cumulative multi-hit model of CHD pathogenesis.
Advances in Diagnosis and Remaining Gaps - High-resolution fetal echocardiography has
boosted prenatal detection of complex CHD from 29.8% to 88.3% over recent decades. National
screening initiatives, notably universal newborn pulse-oximetry, achieve >97% specificity in
identifying critical cyanotic lesions. Yet, in low-resource settings—where fewer than half of
major CHDs are detected prenatally—diagnostic delays persist, contributing to preventable
morbidity and mortality [1,4]. Strengthening physical-examination screening and integrating
low-cost pulse-oximetry at birth can bridge these gaps.
Health Economics and Long-Term Outcomes - Lifetime healthcare costs for CHD survivors
scale with defect complexity, ranging from median ~$12 761 for ASD repairs to >$55 000 for
arterial switch operations. As survival improves (>81% survive to 35 years), the chronic care
burden—including repeated interventions, arrhythmia management, and heart failure
treatments—escalates. Neurodevelopmental and behavioral comorbidities further increase
resource utilization and underscore the necessity of integrated psychosocial support .
Limitations and Future Directions - Our study relies on published registries that vary in case
definitions and inclusion of trivial lesions, potentially inflating heterogeneity. Under-
ascertainment in low-income regions and differential termination practices also bias prevalence
estimates.
Future research should prioritize: Standardized registries with uniform diagnostic criteria across
income settings . Genomic investigations to elucidate genetic architectures underlying non-
syndromic CHDs. Implementation science to optimize low-cost screening (e.g., pulse-oximetry)
and tele-echocardiography in remote areas. Longitudinal cohorts assessing late-life outcomes,
including neurocognitive trajectories and quality-of-life metrics.
By addressing these gaps, the field can move toward equitable CHD care and prevention globally.
CONCLUSION
Across more than four decades of study, the birth prevalence of congenital heart defects (CHDs)
has nearly doubled globally, from approximately 4.0 to 9.41 per 1,000 live births by 2017, driven
by both genuine incidence increases and enhanced case ascertainment [1, 2]. Cyanotic lesions,
while comprising only ~27% of all CHDs, account for disproportionately high early-life
morbidity and mortality, and their survivors face elevated risks of neurodevelopmental and
metabolic comorbidities [3, 4]. Significant regional disparities persist, with lower reported
prevalence in Africa (≈7.2‰) reflecting under-diagnosis, contrasted with rates exceeding 11‰ in
North America [2, 5]. Maternal infections (notably rubella) increase CHD risk nearly threefold,
and consanguinity confers a 1.7-fold risk elevation, underscoring the multifactorial etiology of
CHDs [6, 7]. Advances in fetal echocardiography and universal newborn pulse-oximetry have
markedly improved early detection in high-resource settings, yet diagnostic gaps in low- and
middle-income countries (LMICs) contribute to preventable morbidity and mortality [8, 9]. As
survival to adulthood now exceeds 80% for many CHD subtypes, the lifelong health-care and
psychosocial burdens—including repeat interventions, arrhythmia management, and
neurodevelopmental support—demand integrated, multidisciplinary care models [10, 11].
Summary of Key Findings - Rising Prevalence: Global CHD birth prevalence increased from
~4.0 to 9.41 per 1,000 live births between 1970 and 2017 [1, 2]. Subtype Distribution: Acyanotic
defects predominate (~73%), but cyanotic lesions (~27%) bear higher early-life mortality and
long-term neurodevelopmental risks [3, 4]. Regional Disparities: Under-ascertainment in Africa
(≈7.2‰) and other LMICs contrasts with higher reported rates in North America (≈11.3‰) and
Europe (≈9.8‰) [2, 5]. Risk Factors: Maternal rubella exposure (OR ≈2.8) and consanguinity
(OR ≈1.7) are significant, modifiable risk determinants [6, 7]. Detection Advances & Gaps:
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
890
Prenatal detection of critical CHDs rose to >88% in high-resource regions, yet <50% in many
LMICs [8, 9]. Long-Term Burden: Improved survival (>81% to age 35) transfers care demands
into adulthood, with substantial lifetime costs and neurodevelopmental sequelae [10, 11].
Clinical and Public Health Implications - Early and accurate identification of CHDs is essential
to reduce morbidity and mortality. High-resolution fetal echocardiography and pulse-oximetry
screening should be standard in perinatal care pathways, with training and equipment scaled to
underserved regions [8, 9]. Genetic counseling and rubella vaccination programs must be
integrated into preconception and antenatal services to mitigate modifiable risks [6, 7].
Additionally, as CHD survivors increasingly reach adulthood, health systems should develop
lifelong, multidisciplinary follow-up clinics to address cardiac, neurodevelopmental, and
psychosocial needs [10, 11].
Recommendations and Future Directions - Expand Surveillance: Establish and harmonize
population-based CHD registries in all regions, ensuring uniform case definitions and data
quality [1, 2]. Scale Diagnostic Capacity: Deploy portable echocardiography and pulse-oximetry
in LMICs, complemented by telemedicine links to specialized centers [8, 9]. Strengthen
Preventive Interventions: Maintain rubella elimination goals through sustained MMR
immunization, and offer consanguinity counseling in high-prevalence communities [6, 7]. Invest
in Genomic Research: Prioritize large-scale genomic and environmental exposure studies to
unravel CHD etiologies and identify at-risk populations [4, 10]. Develop Lifelong Care Models:
Create integrated clinics combining cardiology, neurology, psychology, and social services to
support CHD survivors across the lifespan [10, 11]. Economic Evaluations: Conduct cost-
effectiveness analyses of early screening and intervention strategies to guide resource allocation
[9]. By implementing these measures, stakeholders can work toward equitable CHD detection,
prevention, and care, ultimately reducing the global burden of congenital heart disease.
RECOMMENDATIONS
1.
Strengthen Surveillance
: Implement standardized birth defect registries in low-resource
regions.
2.
Prenatal Screening
: Expand fetal echocardiography access, especially for high‐risk
pregnancies.
3.
Vaccination Programs
: Intensify rubella immunization to reduce infection‐associated
CHDs.
4.
Genetic Counseling
: Offer consanguinity education and counseling in at-risk populations.
References
1.
Van der Linde D, et al. Global birth prevalence of congenital heart defects 1970–2017: a
systematic review and meta‐analysis.
Int J Epidemiol
. 2018;48(2):455–463
.
2.
CDC. Data and Statistics on Congenital Heart Defects. 2025.
CDC.gov
3.
Hoffman JIE, Kaplan S. The incidence of congenital heart disease.
J Am Coll Cardiol
.
2002;39(12):1890–1900.
4.
Liu Y, et al. Population‐Based Estimates of the Prevalence of Children With Congenital
Heart Defects.
Circ Cardiovasc Qual Outcomes
. 2024; (Preprint)
5.
Craig BP, et al. Global prevalence of congenital heart disease in school‐age children: a
systematic review.
Int J Cardiol
. 2021;334:139–146
.
6.
Sulak M, et al. Global prevalence of congenital heart diseases in infants.
Paediatr Int
.
2024;66(4):e15002
7.
Liu Y, et al. Global birth prevalence of congenital heart defects 1970–2017.
Oxford
Academic
. 2018;48:455–463
.
https://ijmri.de/index.php/jmsi
volume 4, issue 3, 2025
891
8.
Children’s Heart Foundation. CHD Facts. 2025
9.
Hadley LG, et al. Incidence and types of congenital heart disease at a referral hospital: A
Frontiers in Pediatrics study. 2023
10.
Wikipedia. Congenital heart defect. (Last updated Apr 2025)
.
11.
Health.com. What Is Congenital Heart Disease? 2023
.
